Equities

Novacyt SA

Novacyt SA

Actions
Health CareMedical Equipment and Services
  • Price (EUR)0.581
  • Today's Change-0.019 / -3.17%
  • Shares traded165.23k
  • 1 Year change+21.04%
  • Beta-2.7360
Data delayed at least 15 minutes, as of Jul 05 2024 16:35 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Novacyt SA is a France-based company providing biotechnological solutions. The Company develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The Company provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The Company develops secure automated cytology named NovaPrep Processor System. Novacyt SA offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The Company creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle. Novacyt SA is present in France and internationally through a network of distributors.

  • Revenue in EUR (TTM)9.30m
  • Net income in EUR-29.90m
  • Incorporated2006
  • Employees222.00
  • Location
    Novacyt SA13 avenue Morane SaulnierVELIZY VILLACOUBLAY 78140FranceFRA
  • Phone+33 139465104
  • Fax+33 130700532
  • Websitehttps://novacyt.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Acticor Biotech SA0.00-18.65m9.45m24.00--20.12-----1.68-1.680.000.02980.00----0.00-145.59---297.22-------------9.320.9504-------25.94------
Plant Advanced Technologies PAT SA1.68m79.16k15.53m27.00193.241.8126.789.230.07250.07251.547.730.1118-0.41231.6062,278.520.5262-3.530.6534-4.39128.03134.214.71-33.160.4183-15.320.3402--8.568.05119.67-38.00----
Oncodesign Precision Medicine Opm SA1.07m-8.09m18.46m22.00--4.57--17.22-0.4863-0.48630.06450.22190.0613--1.3948,735.00-46.23---63.87--130.48---754.61------0.7052---86.57---3,399.73------
Phaxiam Therapeutics SA1.33m-23.49m20.16m51.00--0.5184--15.20-5.14-5.140.29013.900.0273--14.8226,000.00-48.37-50.69-66.94-66.25-----1,771.42-1,009.09---70.210.3412---80.05-21.50-10,201.75---56.68--
Poxel SA1.55m-44.24m23.51m30.00------15.21-1.44-1.440.0507-1.220.0597--5.4230,920.00-170.71-31.97-432.50-55.940.1294---2,861.58-101.47---4.0811.28---94.97-33.77-32.13---8.49--
Valbiotis SA4.73m-7.37m24.01m52.00--1.22--5.07-0.5904-0.59040.37981.240.15643.3617.8391,019.23-24.35-32.92-33.77-46.3648.7653.15-155.67-418.873.38-38.190.2598--502.93126.7340.16---21.71--
Nfl Biosciences SAS0.00-3.48m26.01m3.00--6.54-----0.5396-0.53960.000.40970.00----0.00-80.79---125.59--------------0.0228-------149.78------
Predilife SA317.79k-4.22m26.04m19.00------81.95-1.14-1.140.0858-1.060.0695--2.0517,030.55-92.43-89.36-129.39-123.8197.2583.94-1,329.21-1,901.22---6.232.20--10.1179.85-15.58---18.51--
Gensight Biologics SA1.27m-26.22m32.28m16.00------25.48-0.5427-0.54270.0269-0.47260.0723--2,534.0079,187.50-149.52-79.44---144.54-----2,069.53-1,036.27---------50.93--5.09---58.28--
genOway SA20.05m1.57m38.21m133.0023.132.209.521.910.17820.17822.281.880.6190.7733.10150,724.704.840.21666.640.304895.8294.827.820.41771.9528.110.3047--17.5513.16101.5522.35----
Fermentalg SA4.06m-14.15m38.39m62.00--0.7385--9.46-0.3176-0.31760.09170.60330.07530.5333.3565,451.61-24.63-21.94-26.79-24.7113.2114.73-327.08-248.953.53-60.940.3323---46.9475.18-43.29---10.93--
Abionyx Pharma SA4.64m-3.52m39.79m61.00--4.98--8.58-0.121-0.1210.15810.2460.302721.864.2076,694.22-22.95-18.82-32.52-28.8713.3214.32-75.82-128.541.70--0.2997---11.6592.8416.36--41.40--
Novacyt SA9.30m-29.90m41.10m222.00--0.324--4.42-0.4234-0.42470.13171.800.05281.330.262241,907.38-16.9617.69-20.7123.8243.2162.82-321.4023.874.98-79.020.00360.00-77.2813.49-269.46---13.46--
Data as of Jul 05 2024. Currency figures normalised to Novacyt SA's reporting currency: Euro EUR

Institutional shareholders

0.06%Per cent of shares held by top holders
HolderShares% Held
American Century Investment Management, Inc.as of 05 Jun 202440.03k0.06%
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.